Vorozole

Vorozole (developmental code name R-76713; former tentative brand name Rizivor) is a triazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.^[1]

Vorozole

Clinical data
Other names	R-76713; Rizivor
ATC code	L02BG05 (WHO)
Pharmacokinetic data
Bioavailability	Very high
Metabolism	Hepatic
Elimination half-life	8 hours
Identifiers
IUPAC name 6-[(4-Chlorophenyl)(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole
CAS Number	129731-10-8 N
PubChem CID	6918191
ChemSpider	5293402 Y
UNII	1E2S9YXV2A
KEGG	D03786 Y
ChEMBL	ChEMBL224060 Y
CompTox Dashboard (EPA)	DTXSID20156230
Chemical and physical data
Formula	C16H13ClN6
Molar mass	324.77 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1ccc(cc1)[C@@H](c2ccc3nnn(c3c2)C)n4ncnc4
NY (what is this?)  (verify)